Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Montalban-Bravo G, et al. Cell Rep Med. 2024 May 15:101585. doi: 10.1016/j.xcrm.2024.101585. Online ahead of print. Cell Rep Med. 2024. PMID: 38781960 Free article.
Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome.
Sasaki K, Kantarjian H, Montalban-Bravo G, Hammond D, Jabbour E, Kanagal-Shamanna R, Chien K, Garcia-Manero G. Sasaki K, et al. Among authors: montalban bravo g. Clin Lymphoma Myeloma Leuk. 2024 Apr 18:S2152-2650(24)00169-1. doi: 10.1016/j.clml.2024.04.007. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38777652
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN.
Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, Konopleva M, Borthakur G, Daver N, Kanagal-Shammana R, Loghavi S, Qiao W, Huang X, Schneider H, Meyer M, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Leuk Res. 2024 May 11;142:107518. doi: 10.1016/j.leukres.2024.107518. Online ahead of print. Leuk Res. 2024. PMID: 38744144
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. Abuasab T, et al. Among authors: montalban bravo g. Leuk Lymphoma. 2024 May 2:1-6. doi: 10.1080/10428194.2024.2347539. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38696743
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Bataller A, et al. Among authors: montalban bravo g. Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print. Haematologica. 2024. PMID: 38695144 Free article.
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: montalban bravo g. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. Lancet Haematol. 2024. PMID: 38548404 Clinical Trial.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bataller A, et al. Among authors: montalban bravo g. Blood Adv. 2024 Mar 21:bloodadvances.2024012565. doi: 10.1182/bloodadvances.2024012565. Online ahead of print. Blood Adv. 2024. PMID: 38513082
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, Montalban-Bravo G, Adema V, Wildeman B, Kanagal-Shamanna R, Bazinet A, Chifotides HT, Thongon N, Calvo X, Hernández-Rivas JM, Díez-Campelo M, Garcia-Manero G, Colla S. Rodriguez-Sevilla JJ, et al. Among authors: montalban bravo g. Nat Commun. 2024 Mar 18;15(1):2428. doi: 10.1038/s41467-024-46424-3. Nat Commun. 2024. PMID: 38499526 Free PMC article.
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Chien KS, et al. Among authors: montalban bravo g. Cancer Med. 2024 Mar;13(5):e7093. doi: 10.1002/cam4.7093. Cancer Med. 2024. PMID: 38497538 Free PMC article.
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Bazinet A, et al. Among authors: montalban bravo g. Lancet Haematol. 2024 Apr;11(4):e276-e286. doi: 10.1016/S2352-3026(24)00033-4. Epub 2024 Mar 4. Lancet Haematol. 2024. PMID: 38452788 Clinical Trial.
118 results